CD274 and cancer: Although direct costs of introducing these treatments in the Portuguese market are expected to rise over the next years in parallel with the increased uptake of PD-(L)1 inhibitors, growing ageing and longevity of the population, and higher incidence of cancer, this will be partly offset by a reduction in the burden of end-of-life costs and indirect costs related to patient productivity lost to cancer.